Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
YH-25724 by Boehringer Ingelheim International for Obesity: Likelihood of Approval
YH-25724 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Obesity. According to GlobalData, Phase...
Data Insights
YH-25724 by Boehringer Ingelheim International for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval
YH-25724 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metabolic Dysfunction-Associated Steatotic Liver Disease...